Advanced Technology Ventures News

PerkinElmer, Inc. , a global leader in maternal and fetal health, and Verinata Health, an Illumina company and innovator of non-invasive prenatal tests , today announced that several of the top health insurance plans have expanded coverage of the verifiA prenatal test for a variety of potential fetal health risks to over 80 million covered lives.

PerkinElmer, Inc. , a global leader focused on improving the health and safety of people and the environment, today announced that the Company will present at the UBS Global Healthcare Conference on Monday, May 20, 2013, at 4:00 pm Eastern Time at the Sheraton New York Hotel and Towers in New York City.

Mizuho currently has a buy rating on the stock. A number of other analysts have also recently weighed in on PKI.

The meeting program will feature world-renowned experts presenting key insights on finding, understanding, and acting upon the causes and effects of disease including cancer, diabetes and heart disease.

's stock had its "neutral" rating restated by Zacks in a research report issued to clients and investors on Monday, StocKRatingsNetwork.com reports.

The firm currently has a "buy" rating on the stock. Other equities research analysts have also recently issued reports about the stock.

PerkinElmer issued an update on its FY13 earnings guidance on Thursday morning. The company provided earnings per share guidance of $2.00-2.10 for the period, compared to the Thomson Reuters consensus estimate of $2.29, AnalystRatingsNetwork.com reports.

PerkinElmer, Inc. , a global leader focused on improving the health and safety of people and the environment, today reported financial results for the first quarter ended March 31, 2013.